Literature DB >> 20091746

Breviscapine-induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity.

Yulin Wu1, Qianqian Fan, Na Lu, Lei Tao, Yuan Gao, Qi Qi, Qinglong Guo.   

Abstract

Breviscapine is a flavonoid constituent isolated from a traditional Chinese herb Erigerin breviscapus (Vant.) Hand-Mazz. To investigate the apoptosis-inducing effect of breviscapine on human hepatocellular carcinoma cell line HepG2 and explore the relative molecular mechanisms. HepG2 cells were treated with breviscapine at different concentrations and the inhibitory rate was analyzed by MTT assay. The morphological changes in cells were observed under an inverted light microscope and a fluorescence microscope and the apoptosis rate were detected by flow cytometry. Western blot was used to evaluate the protein expression. The viability of HepG2 cells was markedly inhibited in a concentration-dependent manner and obvious morphological changes were confirmed, including condensed chromatin and reduction in volume. The increased percentage of apoptotic cells was displayed by flow cytometry and the altered expression level of several apoptosis-associated proteins, Bcl-2, Bax and caspase-3, was detected by western blot. It is first discovered that breviscapine exhibited potential antitumor activity, induces remarkable apoptosis in HepG2 cells and promises to be a new candidate in future cancer therapy. Copyright (c) 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20091746     DOI: 10.1002/ptr.3002

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  9 in total

Review 1.  Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.

Authors:  Bingxue Shang; Zhifei Cao; Quansheng Zhou
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

2.  Breviscapine suppresses the growth of non-small cell lung cancer by enhancing microRNA-7 expression.

Authors:  Jian Zeng; Shunv Cai
Journal:  J Biosci       Date:  2017-03       Impact factor: 1.826

3.  Feng-Liao-Chang-Wei-Kang Combined with 5-Fluorouracil Synergistically Suppresses Colitis-Associated Colorectal Cancer via the IL-6/STAT3 Signalling Pathway.

Authors:  Lifan Zhong; Fan Yang; Lianfang Gan; Zhaoxin Yang; Shuhong Tian; Mianqing Huang; Chuanzhu Lv; Ling Huang
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-03       Impact factor: 2.629

4.  Anticancer mechanism of breviscapine in non-small cell lung cancer A549 cells acts via ROS-mediated upregulation of IGFBP4.

Authors:  Weitian Wei; Liang Wang; Liwei Xu; Jian Zeng
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 2.895

5.  The combination of TRAIL and isoflavones enhances apoptosis in cancer cells.

Authors:  Joanna Bronikowska; Ewelina Szliszka; Zenon P Czuba; Dariusz Zwolinski; Dariusz Szmydki; Wojciech Krol
Journal:  Molecules       Date:  2010-03-22       Impact factor: 4.411

6.  Extracts of Lycoris aurea induce apoptosis in murine sarcoma S180 cells.

Authors:  Na Liao; Mingzhang Ao; Peng Zhang; Longjiang Yu
Journal:  Molecules       Date:  2012-03-26       Impact factor: 4.411

7.  Breviscapine ameliorates CCl4‑induced liver injury in mice through inhibiting inflammatory apoptotic response and ROS generation.

Authors:  Yu Liu; Pei-Hao Wen; Xin-Xue Zhang; Yang Dai; Qiang He
Journal:  Int J Mol Med       Date:  2018-05-02       Impact factor: 4.101

8.  Flavonoid compound breviscapine suppresses human osteosarcoma Saos-2 progression property and induces apoptosis by regulating mitochondria-dependent pathway.

Authors:  Zhijun Wang; Hongyan Li; Jiyuan Yan; Yang Liu
Journal:  J Biochem Mol Toxicol       Date:  2020-09-24       Impact factor: 3.642

9.  EGR1 promoted anticancer effects of Scutellarin via regulating LINC00857/miR-150-5p/c-Myc in osteosarcoma.

Authors:  Jian Han; Peng Wang; Xin Xia; Li Zhang; He Zhang; Yu Huang; Xiaodong Li; Wenzhi Zhao; Lu Zhang
Journal:  J Cell Mol Med       Date:  2021-08-04       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.